|
|
 |
 |
|
|
| Scientific Program |
| |
Thursday, September 6, 2007
Friday, September 7, 2007
Hall A
| Session 1 |
|
|
08:30-10:00 |
Multiple Sclerosis (MS)
Sponsored by an unrestricted grant from Biogen Idec |
|
|
Capsule: Many people believe that MS is a syndrome rather than a single nosologic entity. The role of auto-immune processes is also still problematic and the respective role of T cells and B cells is debated. This has important implications for therapy. |
| |
Chairpersons: G. Comi, Italy; Z. Stelmasiak, Poland |
| |
|
|
08:30-09:30 |
Debate: MS is a single nosologic entity due to an auto-immune mechanism |
|
|
Yes: H.P. Hartung, Germany |
| |
No: I. Steiner, Israel |
| |
|
|
09:30-10:00 |
Alemtuzumab (Campath) in early MS |
| |
V. Brinar, Croatia |
| |
|
|
10:00-10:30 |
Coffee Break |
| |
|
| Session 2 |
|
|
10:30-12:30 |
Anti-Interferon Antibodies
Sponsored by an unrestricted grant from TEVA & Sanofi Aventis |
|
|
Capsule: Treatment with interferons (IFNs) provokes in some cases the production of naturalizing antibodies (NABs). Their clinical significance is still unclear and their management is still under debate. |
| |
Chairpersons: V. Brinar, Croatia; A. Miller, Israel |
| |
|
|
10:30-11:30 |
Weak points in MS diagnosis |
| |
G. Giovannoni, UK |
| 11:00-11:30 |
Role of Biomarkers in diagnosis and treatment |
| |
K. Selmaj, Poland |
|
|
|
| 11:30-12:30 |
Debate: Does the presence of NABs against IFNs necessitate a switch to another class of therapy |
|
|
Yes: P.S. Sorensen, Denmark |
| |
No: J. Oger, Canada |
|
|
|
12:30-13:30 |
Lunch Break |
|
|
|
| Session 3 |
|
|
13:30-15:30 |
Treatment Strategies for Multiple Sclerosis
Sponsored in part by an unrestricted grant from Bayer Schering Pharma |
|
|
Capsule: Many issues regarding when and how to start treatment and what are the future avenues are not clear! |
| |
Chairpersons: W. Carroll, Australia; K. Rejdak, Poland |
| |
|
|
13:30-14:30 |
Debate: Clinically isolated syndromes (CIS): to treat or not to treat |
|
|
Start early: G. Comi, Italy |
| |
No hurry: A. Siva, Turkey |
|
|
|
|
14:30-15:30 |
Debate: Is stem cell therapy an imminent treatment in advanced MS? |
| |
Stem cell therapy in MS is a real option: G. Martino, Italy |
|
|
Bioethical aspects of human embryonic stem cells are still an issue: M. Revel, Israel |
| |
|
| 15:30-16:00 |
Coffee Break |
| |
|
| Session 4 |
|
|
16:00-17:30 |
Multiple sclerosis - Neuroproctection |
| |
Sponsored in part by an unrestricted grant from Merck Serono |
| |
Capsule: While there is no doubt that interferons and copaxone can reduce relapse rate in MS, it is still unclear if, how, and to what extent they can reduce the Accumulation of disability. |
| |
Chairpersons: G. Comi, Italy; I. Milonas, Greece |
| |
|
| 16:00-17:00 |
Debate: Neuroprotective effect of IFNs and copaxone in MS - myth or reality? |
| |
Myth: C. Constantinescu, UK |
| |
Reality: X. Montalban, Spain |
| |
|
| Session 5 |
|
| 17:00-18:00 |
Free Communications -Multiple sclerosis |
| |
Chairpersons: P. Calabrese, Germany; M. Sakkopoulou, Greece |
| |
|
|
17:00-17:15 |
Immediate treatment with IFNB-1b after a first event suggestive of MS delays persistant neurological impairment |
| |
X. Montalban, Spain |
|
17:15-17:30 |
Use of stem cells preparations for the treatment of patients suffering from multiple sclerosis adn immunological control of treatment efficiency |
| |
N. Mkrtchyan, Russia |
|
17:30-17:45 |
Comparison of interferon beta productions and azathioprine in treatment of relapsing-remitting multiple sclerosis |
| |
M. Janghorbani, Iran |
| 17:45-18:00 |
Facial Palsy in Iranian patients with Multiple Sclerosis |
| |
Y. IIkhchoui, Iran |
Friday, September 7, 2007
Hall B
| Session 6 |
|
|
08:30-10:00 |
Management of Transient Ischemic Attacks (TIA’s) |
|
|
Capsule: TIA’s are frequently undiagnosed, misdiagnosed or mistreated. |
| |
Chairpersons: N. Bornstein, Israel; K. Einhaeupl, Germany |
| |
|
|
08:30-09:30 |
Debate: Testing for right-to-left cardiac shunt |
| |
The PFO should be closed before the first cerebral event: B. Meier, Switzerland |
| |
No: The cost is too high, the yield too low: C. Diener, Germany |
| |
|
|
09:30-10:00 |
When and how to look for CADASIL and Fabry? |
| |
A. Rolfs, Germany |
| |
|
|
10:00-10:30 |
Coffee Break |
| |
|
| Session 7 |
|
|
10:30-12:30 |
Interventions in Secondary Stroke Prevention |
| |
Chairpersons: O. Bajenaru, Romania; O. Bartko, Slovakia |
| |
|
|
10:30-11:30 |
Debate: Drug therapy for TIA |
| |
Immediate aspirin and dipyridamole: C. Diener, Germany |
| |
Immediate clopidogrel: J. Streifler, Israel |
| |
|
|
11:30-12:30 |
Debate: Carotid stenting is better than carotid endarterectomy |
|
|
Capsule: Stenting is an effective procedure and in time may replace surgery for most patients. |
| |
Yes: J. Wojczal, Poland |
| |
No: N. Bornstein, Israel |
|
|
|
|
12:30-13:30 |
Lunch Break |
|
|
|
| Session 8 |
|
|
13:30-15:30 |
Management of Acute Stroke |
|
|
Capsule: Patients with acute stroke are frequently admitted to general medical or neurological wards, where important factors are not attended to, leading to clinical deterioration |
| |
Chairpersons: V. Hachinksi, Canada; J. Streifler, Israel |
| |
|
| 13:30-14:00 |
Management of hyperglycemia and hypertension in acute stroke |
|
G.M. Boysen, Denmark |
| 14:00-14:30 |
tPA beyond time and age limits |
|
E. Stolz, Germany |
| 14:30-15:00 |
Intra-arterial thrombolysis |
|
A. Ciccone, Italy |
|
15:00-15:30 |
Discussion |
| |
|
|
15:30-16:00 |
Coffee Break |
|
|
|
| Session 9 |
|
|
16:00-18:00 |
Pathogenesis of Parkinson's Disease (PD)
Sponsored in part by unrestricted grants from SCHWARZ PHARMA and ORION |
|
|
Capsule: Despite much research, the pathogenesis of PD is still contested. Is there one cause that can be thought of as initiating the cascade? |
|
|
Chairpersons: V. Kostic, Serbia; M. Ghabaee, Iran |
| |
|
|
16:00-16:30 |
PD is a mitochondrial dysfunction disease |
|
|
M. Youdin, Israel |
|
16:30-17:00 |
PD is due to protein dysfunction |
|
|
W. Olanow, USA |
|
17:00-17:30 |
Is PD a ferrinopathy? |
|
|
D. Berg, Germany |
|
17:30-18:00 |
Olfactory dysfunction in early PD suggests that the disease is caused by a toxin |
| |
H. Reichmann, Germany |
| |
|
| Session 10 |
|
| 18:00-18:30 |
Free Communications - Various Topics |
| |
Chairpersons: K. Bayulkem, Turkey; J. Wojczal, Poland |
| |
|
| 18:00-18:10 |
Visual loss in idiopathic intracranial hypertension despite normal intracranial pressure |
| |
H.E. Killer, Switzerland |
| 18:10-18:20 |
Aspirin resistance correction in the aged patients after first ever ischemic stroke |
| |
V.G. Karepov, Israel |
|
18:20-18:30
|
|
| |
Z. Rozhkova, Ukraine |
Friday, September 7, 2007
Hall C
| Session 11 |
|
|
08:30–10:00 |
Autoimmune Dementia |
|
|
Capsule: In addition to the common causes of dementia, some patients are thought to have an underlying autoimmune mechanism. When should these be considered and how should they be treated? |
|
|
Chairpersons: A. Kertesz, Canada; T.A. Treves, Israel |
| |
|
|
08:30-08:50 |
|
|
|
A. Chaudhuri, UK |
|
08:50-09:10 |
|
|
|
A. Vincent, UK |
|
09:10-9:30 |
|
|
|
J. Chapman, Israel |
|
09:30-09:50 |
|
| |
P. Calabrese, Germany |
|
09:50-10:00 |
Discussion |
|
|
|
| Session 12 |
|
|
10:00-10:30 |
Coffee Break |
|
|
|
|
10:30-11:30 |
A Cure for Alzheimer's Disease (AD) |
|
|
Capsule: Because beta-amyloid is a hallmark of AD, attempts are being made to eliminate this protein. One of the new methods to achieve this is through anti-amyloid immunization, while a competitive method is by inhibition of APP-cleaving enzymes. |
| |
Chairpersons: J. Callaway, USA; M. Youdim; Israel |
| |
|
|
|
Debate: Immunization will cure AD |
|
|
Yes: R. Nitsch, Switzerland |
|
|
No: E. Giacobini, Switzerland |
|
|
|
| Session 13 |
|
|
11:30-12:30 |
Treatment of Cognitive Impairment |
|
|
Capsule: Cholinesterase inhibitors (ChEI's) and memantine are the only approved drugs for the treatment of Alzheimer’s disease (AD), but there is debate on their efficacy, both in MCI and (even more) in advanced AD. |
|
|
Chairpersons: L. Battistin, Italy; D. Muresanu, Romania |
| |
|
|
11:30-12:00 |
|
|
|
M. Youdim, Israel |
|
12:00-12:30 |
|
|
|
H. Fillit, USA |
|
|
|
|
12:30-13:30 |
Lunch Break |
|
|
|
| Session 14 |
|
|
13:30-15:30 |
Non-Alzheimer Dementias |
|
|
Chairpersons: M. Davidson, Israel; P.J. Visser, The Netherlands |
| |
|
|
13:30-14:30 |
Debate: Vascular cognitive impairment is a misleading concept |
|
|
Capsule: Dementia or milder forms of cognitive decline can occure following obvious strokes or in conjunction with vascular risk factors. Recently the term vascular cognitive impairment has been suggested to encompass vascular dementia, Biswanger’s disease and multi-infarct dementia. However, this term has not been unchallenged. |
|
|
|
|
|
|
|
|
|
|
14:30-15:30 |
Debate: Dementia with Lewy bodies and dementia of Parkinson’s disease are the same disorder |
|
|
Yes: L. Battistin, Italy |
|
|
No: G. Ransmayr, Austria |
|
|
|
|
15:30–16:00 |
Coffee Break |
|
|
|
| Session 15 |
|
|
16:00-18:00 |
Mild Cognitive Impairment (MCI) |
|
|
Capsule: Dementia typically develops insidiously. An intermediate stage between normai aging and dementia termed mild cognitive impairment (MCI) is still not well understood nor generally accepted and there is no agreement on how it should be treated. |
|
|
Chairpersons: Y. Lerman, Israel; P. Werner, Israel |
| |
|
|
16:00-17:00 |
Debate: Is MCI a useful concept? |
|
|
|
|
|
|
| |
|
|
17:00-18:00 |
Debate: Treatment of MCI is available and should be given |
|
|
|
|
|
No: P.J. Visser, The Netherlands |
|
|
|
| Session 16 |
|
|
18:00-18:30 |
Free Communications - Various Topics |
| |
Chairpersons: B. Popescu, Romania; N. Razon, Israel |
| |
|
| 18:00-18:10 |
Immunotherapy of neurological paraneoplastic syndromes - disappointing or effective? |
| |
S. Michalak, Poland |
|
18:10-18:20 |
Determinants of functional loss in patients with glioma in eloquent areas: a pre and postoperative fMRI study |
| |
V. Gonzalez-Felipe, Germany |
|
18:20-18:30 |
Activated Factor VII (Novoseven) for Acute Intracerebral Hemorrhage: Experience of 15 Cases From a Single Centre |
| |
S. Kumar, India |
Saturday, September 8, 2007
Hall A
| Session 17 |
|
|
08:30-10:00 |
Psychogenic Neurological Disorders |
|
|
Capsule: Clinicians are still facing frequent difficulties in differentiating "organic" from "functional" disorders. |
| |
Chairpersons: T. Lempert, Germany; I. Steiner, Israel |
| |
|
|
08:30-08:50 |
Is psychogenic dystonia a valid diagnosis? |
|
|
K. Black, USA |
|
08:50-9:10 |
Is Regional Sympathetic Dystrophy (RSD) - Dystonia an organic disease? |
|
|
M. Hallet, USA |
| 09:10-09:30 |
|
| |
C.Elger, Germany |
| 9:30-9:50 |
Vertigo as a psychogenic disorder |
| |
M. Strupp, Germany |
| 09:50-10:00 |
Discussion |
| |
|
|
10:00-10:30 |
Coffee Break |
|
|
|
| Session 18 |
|
|
12:30-14:30 |
Satellite Lunch Symposium
Sponsored by Elan
Can Neurodegenerative Diseases be Slowed or Reversed?
Elan's Look into the Future |
|
|
|
| 12:30-12:40 |
Opening remarks |
| |
A.D. Korczyn, Israel |
| 12:40-13:20 |
Natalizumab and Beyond: Elan’s Look into the future of the science of neurodegeneration |
| |
T. Yednock, USA |
| 13:20-13:50 |
Can Alzheimer’s disease progression be Slowed or reversed? |
| |
D. Schenk, USA |
| 13:50-14:15 |
Are anti-amyloid therapies the answer? |
| |
R. Jones, USA |
| 14:15-14:30 |
Q & A; Closing remarks |
| |
A.D. Korczyn, Israel |
| |
|
| Session 19 |
|
|
16:30-18:00 |
Free Communications - Stroke |
| |
Chairperson: V. Karepov, Israel |
| |
|
|
16:30-16:45 |
Protection from brain damage and bacterial infection in murine stroke by the novel caspase-inhibitor Q-VD-OPH |
|
|
J. Braun, Germany |
|
16:45-17:00 |
Carotid endarterectomy vs carotid stenting - Critical overview and leader expert's opionion |
|
|
D. Bartko, Slovakia |
| 17:00-17:15 |
Is mannitol useful in intracerebral hemorrhage? |
| |
U. Misra, India |
|
17:15-17:30 |
Combined Therapy of tPA and UK for actute ischemic stroke |
|
|
W. Zhang , China |
|
17:30-17:45 |
The incidence and determinations of Sleep Apnea Syndrome in patients with spinal cord injury and stroke |
|
|
T. Van Bezeij, The Netherlands |
| 17:45-18:00 |
Hemidystonia in stroke |
|
|
A. Subbiah, India |
Saturday, September 8, 2007
Hall B
| Session 20 |
|
|
08:30-10:00 |
Autoimmune Disorders
Sponsored in part by an unrestricted grant from Talecris |
|
|
Capsule: The pathogenesis of several autoimmune diseases is still unclear. What is the role of antibodies and which treatements are available? |
| |
Chairpersons: N. Mironov, Russia; Z. Petelin Gadze, Croatia |
| |
|
|
08:30-09:00 |
The autoimmune spectrum of myasthenia |
|
|
A. Vincent, UK |
| |
|
|
09:00-10:00 |
Debate: Treatment of chronic inflammatory demyelinating neuropathy (CIDP) |
| |
Treatment with IVIG: H.P. Hartung, Germany |
| |
Other Treatments: J. Chapman, Israel |
| |
|
|
10:00-10:30 |
Coffee Break |
| |
|
| Session 21 |
|
|
14:30-16:00 |
Epilepsy |
|
Capsule: Patients with epilepsy who are unresponsive to drugs should be considered for surgery and the identificatin of suitable cases usually involves expensive videotaping and seizure monitoring. |
| |
Chairpersons: S. Benbadis, USA; D. Schmidt, Germany |
|
14:30-15:15 |
Debate: Is video EEG monitoring always necessary before performing epilepsy surgery? |
| |
Yes: H. Stefan, Germany |
|
|
No: M.R. Sperling, USA |
| |
|
|
15:15-16:00 |
Debate: Deep Brain Stimulation (DBS) is ready for clinical use in refractory epilepsy |
| |
Yes: P. Boon, Belgium |
|
|
No: C. Elger, Germany |
| |
|
|
16:00-16:30 |
Coffee Break |
| |
|
| Session 22 |
|
| 16:30-17:30 |
Resistant Epilepsy |
|
Capsule: About 20% of epilepsy patients do not respond adequately to drugs. What is the treatment of choice? |
|
|
Chairpersons: P. Boon, Belgium; C. Elger, Germany |
| |
|
|
|
Debate: What to do when two drugs fail? |
|
|
Try a third drug: D. Schmidt, Germany |
|
|
Vagal Nerve Stimulation (in suitable patients): K. Vonck, Belgium |
|
|
Ablative surgery: S. Benbadis, USA |
| |
|
|
Session 23 |
|
|
17:30-18:30 |
Free Communications- Various Topics |
|
|
Chairpersons: J.T. Apter, USA; K. Vonck, Belgium |
| |
|
|
17:30-17:45 |
Epilepsies with occipital epileptiform discharges-electronical characteristics |
| |
M. Mazurkiewicz-Beldzinska, Poland |
|
17:45-18:00 |
What role does biofeedback therapy have in the treatment of migraine |
|
|
M. Rashidi, UK |
|
18:00-18:15 |
Lorazepam in treatment of convulsive status epilepticus in children: A randomized controlled trial |
|
|
P. Gupta, India |
| 18:15-18:30 |
Discussion |
Saturday, September 8, 2007
Hall C
| Session 24 |
|
|
08:30-10:00 |
Parkinsons Disease (PD): Early Treatment
Sponsored in part by an unrestricted grant from Merck Serono |
|
|
Capsule: Motor complications are disabling complications of PD therapy. How can they be avoided? |
| |
Chairpersons: O. Bajenaru, Romania; A. Gordin, Finland |
| |
|
|
08:30-09:00 |
MAOB-inhibitors should be the first line drug in early PD |
| |
A. Ludolph, Germany |
|
09:00-09:30 |
Dopamine Agonists are the treatment of choice in early PD |
| |
M. Guttman, Canada |
|
09:30-10:00 |
New Treatment Advances in early PD |
| |
F. Stocchi, Italy |
|
|
|
| 10:00-10:30 |
Coffee Break |
| |
|
| Session 25 |
|
|
10:30-12:30
|
Neuroprotection and Neuroplasticity
Sponsored by SSNN |
|
Capsule: One of the important issues in stroke therapy is the protection of neurons in the penumbra region. Several Studies have failed to identify treatments which could help. Why and how to overcome these difficulties? |
| |
Chairpersons: A. Ludolph, Germany; L. Vecsei, Hungary |
| |
|
| 10:30-10:50 |
Blood-brain barrier and neuroprotection |
| |
H.S Shanker, Sweden |
| 10:50-11:10 |
Vascular Protection in Stroke |
| |
O. Bajenaru, Romania |
| 11:10-11:30 |
Neuroprotection in acute ischemic stroke - Is there still hope? |
| |
N. Bornstein, Israel |
| 11:30-11:50 |
Prophylaxis in neuroprotection. An innovative approach |
| |
L. Csiba, Hungary |
| 11:50-12:10 |
Neuroprotection and neuroplasticity - a dualistic vision of a continuous process |
| |
D. Muresanu, Romania |
| 12:10-12:30 |
Discussion |
|
|
|
| Session 26 |
|
| 14:30-16:00 |
Treatment of Advanced PD |
| |
Capsule: How can we best control the motor complications in advanced PD? |
| |
Chairpersons: M. Guttman, Canada; M. Hilz, Germany |
| |
|
| 14:30-14:50 |
Intraduodenal levodopa |
| |
D. Truong, USA |
| 14:50-15:10 |
Apomorphine infusions in complicated PD |
| |
D. Dressler, Germany |
| 15:10-15:30 |
Deep Brain Stimulation (DBS) |
| |
A. Kupsch, Germany |
| 15:30-15:50 |
Spheramine-cell therapy |
| |
E. Reissig, Germany |
| 15:50-16:00 |
Discussion |
| |
|
| 16:00-16:30 |
Coffee Break |
| |
|
| Session 27 |
|
| 16:30-17:30 |
Non-Motor Aspects of PD |
|
Capsule: Non dopaminergic symptoms may be more relevant than DA-responsive motor symptoms in PD |
| |
Chairpersons: R. Denglar, Germany; R. Rangel Guerra, Mexico |
| |
|
| 16:30-16:50 |
Is dementia inevitable in PD? |
| |
I. Litvan, USA |
| 16:50-17:10 |
Daytime somnolence in PD - How to avoid and how to treat? |
| |
K.R. Chaudhuri, UK |
| 17:10-17:30 |
Treatment for PD psychosis: Which drug is most useful in clinical practice? |
| |
J.M. Rabey, Israel |
| |
|
| Session 28 |
|
| 17:30-18:30 |
Parkinsonian Syndromes |
| |
Capsule: Movement disorders with Parkinsonian features have been diagnosed using different methods, using different criteria, but the basic question remains of the nosologic entities underlying these neurodegenerative diseases. |
| |
Chairpersons: C. Falup, Romania; J.M. Rabey, Israel |
| |
|
| |
Debate: Are PSP and CBGD the same disease? |
| |
For: A. Kertesz, Canada |
| |
Against: I. Litvan, USA |
Sunday, September 9, 2007
Hall A
| Session 29 |
|
|
08:30-10:00 |
Dystonia
Sponsored in part by an unrestricted grant fromMerz |
| |
Chairpersons: A. Kurdi, Jordan; T.A. Treves, Israel |
| |
|
| |
Debate: Dystonia - disorder of motor programming or motor execution? |
| |
Capsule: Dystonia is traditionally seen as an involuntary movement, leading to treatment strategies using botulinum toxin (BTX). Viewed differently, dystonia is an “unconscious“ rather than “involuntary“ movement, caused by defective “motor routines“ in the motor program. This concept suggests that BTX, when used, should be directed into the muscles causing dystonic movement and also into their antagonists. The possible feedback can affect central mechanisms and might induce long-lasting remission. |
| |
|
| |
P. Kanovsky, Czech Republic |
| |
R. Rosales, Philippines |
| |
|
|
10:00-10:30 |
Coffee Break |
|
|
|
| Session 30 |
|
| 10:30-12:00 |
Restless Legs Syndrome
Sponsored in part by an unrestriced grant from Schwarz Pharma |
|
Capsule: RLS may be the most common movement disorder, but it is still underdiagnosed and there is no consensus on its treatment. |
| |
Chairpersons: R. Horowski, Germany; A. Kupsch, Germany |
| |
|
| 10:30-11:30 |
Debate: Are PLMS and RLS the same disorder? |
| |
Yes: D. Garcia-Borreguero, Spain |
| |
No: M. Zucconi, Italy |
| |
|
| 11:30-12:00 |
Which treatment best avoids augmentation? |
| |
W. Paulus, Germany |
Sunday, September 9, 2007
Hall B
| Session 31 |
|
|
08:30-10:00 |
Treatment of Migraine: Beyond Triptans |
|
|
Capsule: Therapy of chronic headache is frequently unsatisfactory and newer methods for symptomatic therapy are needed. Botulinum toxin injections are such methods, which have still not received wide acceptance. |
| |
Chairpersons: Y. Frank, USA; A. Siva, Turkey |
| |
|
| |
Debate: Botulinum toxin in the treatment of headache |
|
|
Proposition: Botulinum toxin is effective for headache
S. Evers, Germany |
| |
Opposition: Botulinum toxin should be used cautiously
U. Reuter, Germany |
|
|
|
|
10:00-10:30 |
Coffee Break |
| |
|
| Session 32 |
|
|
10:30-11:10 |
Free Communications - Multiple Sclerosis |
| |
Chairpersons: N. Mkrtchyan, Russia; J.A. Moreira, USA |
| |
|
|
10:30-10:40 |
Structural and functional correction of spine and spinal cord disorders for patients affected by multiple sclerosis |
| |
A. Sukhanov, Russia |
| 10:40-10:50 |
Acquired attitude, interpersonal frictions and development of multiple sclerosis |
| |
P. Vassiliu, Greece |
|
10:50-11:00 |
Treatment outcome in multiple sclerosis patients after high-dose chemotherapy (HDCT)+autologous stem cell transplantation (ASCT): Follow up results of prospective multicenter study |
| |
A.A. Novik, Russia |
|
11:00-11:10
|
Influence of interferon-beta switching on neutralizing antibody titers: The Austrian Switch Study (ASS) |
| |
F. Deisenhammer, Austria |
| |
|
| Session 33 |
|
| 11:10-12:00 |
Free Communications - Various Topics |
| |
Chairpersons: P. Kanovsky, Czech Republic; S. Schreiber, Israel |
| |
|
| 11:10-11:20 |
A dramatic effect of nandrolone decanoate in cerebral palsy |
| |
A. Al Mosawi, Iraq |
|
11:20-11:30 |
Long-term use of levetiracetam to treat tics in children and adolescents with Tourette syndrome |
| |
Y. Awaad, USA |
|
11:30-11:40 |
Can patterns of clinical presentation in acute spinal pathology predict diagnosis and treatment in a spine surgical unit? |
| |
T. Thangarajah, UK |
| 11:40-11:50 |
Neuroleptic Malignant Syndrome |
| |
J. Mohtashami, Iran |
| 11:50-12:00 |
Implementing Transcranial Doppler as confirmatory test in brain death criteria |
| |
B. Sheikh, Saudi Arabia |
| |
|
| Session 34 |
|
|
12:00-14:00 |
Optimization of Treatment Benefits in Patients with MS: Exploring the Betaferon Dose-Response Curve
Satellite Symposium Sponsored by Bayer Schering Pharma |
| |
Chairperson: B. Carroll, Australia |
| |
|
| 12:00-12:15 |
Introduction: Current management of MS |
| |
B. Carroll, Australia |
| 12:15-12:45 |
Experience with higher doses of interferon in MS |
| |
O. Fernandez, Spain |
| 12:45-13:05 |
Optimizing management strategies to maximize tolerability and adherence for Betaferon |
| |
K. Baum, Germany |
| 13:05-13:25 |
The BEYOND study |
| |
D. Goodin, USA |
| 13:25-13:45 |
The potential impact of BEYOND on case management strategies |
| |
D. Jeffery, USA |
| 13:45-14:00 |
Questions and Discussion |
| |
B. Carroll, Australia | |
|
|
